Diabetic Foot Ulcers Clinical Trial
Official title:
Utilization of Umbilical Cord Blood-derived Platelet Gel for Treatment of Diabetic Foot Ulcers,a Randomized Double Blind Clinical Trial
Verified date | November 2011 |
Source | Royan Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | Iran: Ethics CommitteeIran: Ministry of Health |
Study type | Interventional |
Diabetes is a multiorgan disease and considered a major health problem in different
societies. One of the complications the pain particularly in the extremities resulting from
a process known as diabetic foot ulcer. The diabetic patients are subjected to many
complications because of foot ulcers, many of them like as chronic wound disease or pressure
ulcers (bed sore). Routinely used medical measures for diabetic foot ulcers are depended to
nursing care and take too long until pain relief. Among many tested materials and works for
wound healing such as debridement, tissue oxygenation, and skin transplantation,
platelet-derived compounds are allocated the pivotal position between investigators to
tissue regeneration and shortening the wound healing process.
Many of platelet components are procured from platelet rich plasma (PRP) from whole blood
donation. Furthermore, it requires to an additional purification step to diminish the volume
and facilitate handling in some studies. It means that platelet concentrates (PCs) may be
obtained leading to more concentrated platelets in lower volume.
Two types of granules in platelet is responsible for storage of many useful and different
growth factors: dense or delta and alpha granules. Platelet-derived growth factors have the
ability to growth and differentiation of numerous cells. Also, the antibacterial effect of
these growth factors has been reported.
To better efficacy and comfortable utilization of platelet, it is feasible to form the
platelet gel and then apply on wound sites.
This study is a double blind randomized controlled trial to evaluate the positive effects of
umbilical cord blood-derived platelet gel in 244 patients with diabetic foot ulcers.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 30 Years to 65 Years |
Eligibility |
Inclusion Criteria: - History of at least 4 weeks hospitalization - Uncontrolled diabetes - ejection fraction > 30% Exclusion Criteria: - mechanical origin for wound - history of infectious, systemic diseases, Immune deficiency and coagulation disorders |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Royan Institute | Tehran |
Lead Sponsor | Collaborator |
---|---|
Royan Institute |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pain | Evaluation the pain reduction by VAS measurement in patients with peripheral artery Disease. | 3 months | Yes |
Primary | ABI | Evaluation the Ankle Brakial Index (ABI) in patients 3 months after PG utilization. | 3 months | Yes |
Secondary | Quality of life | Evaluation the quality of life by SF36 measurement in patients with PAD. | 3months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02652754 -
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
|
Phase 1 | |
Completed |
NCT01070433 -
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Completed |
NCT00971048 -
Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds
|
N/A | |
Terminated |
NCT00762138 -
The AutoloGel™ Post-Market Surveillance (TAPS) Program
|
N/A | |
Completed |
NCT00578604 -
Non-Invasive Assessment of Wound Healing With Optical Methods
|
N/A | |
Completed |
NCT05417425 -
Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers
|
Phase 1 | |
Completed |
NCT02631512 -
Evaluation of Woulgan in Diabetic Foot Ulcer
|
Phase 4 | |
Terminated |
NCT01816633 -
Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT02222376 -
Effect of Topic Pirfenidone in Diabetic Ulcers
|
Phase 3 | |
Completed |
NCT01454401 -
LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01221207 -
Instant Total Contact Cast to Heal Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01291160 -
Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
|
Phase 2/Phase 3 | |
Withdrawn |
NCT01105884 -
Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT00536744 -
Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers
|
Phase 3 | |
Terminated |
NCT00316537 -
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
Completed |
NCT00013299 -
Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3
|
Phase 2 | |
Completed |
NCT00013286 -
A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk
|
Phase 2 | |
Terminated |
NCT02667327 -
A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
|
Phase 3 | |
Not yet recruiting |
NCT00916292 -
Safety Study of Topical Human FGF-1 for Wound Healing
|
Phase 1 | |
Completed |
NCT01154374 -
A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)
|
Phase 2 |